| 34.94 -1.99 (-5.39%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 46.9 | 1-year : | 54.78 |
| Resists | First : | 40.15 | Second : | 46.9 |
| Pivot price | 37.6 |
|||
| Supports | First : | 29.43 | Second : | 22.8 |
| MAs | MA(5) : | 37.93 |
MA(20) : | 37.21  |
| MA(100) : | 23.48 |
MA(250) : | 23.17 |
|
| MACD | MACD : | 2.6 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 36.8 |
D(3) : | 62.4 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 40.15 | Low : | 13.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DNTH ] has closed below the lower bollinger band by 2.0%. Bollinger Bands are 16.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 37.81 - 38.08 | 38.08 - 38.28 |
| Low: | 33.95 - 34.29 | 34.29 - 34.55 |
| Close: | 34.47 - 34.93 | 34.93 - 35.28 |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Thu, 02 Oct 2025
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9% - What's Next? - MarketBeat
Thu, 02 Oct 2025
Phase 2 Myasthenia Gravis Trial Results: Dianthus' Claseprubart Data to Be Unveiled at Major Conference - Stock Titan
Wed, 01 Oct 2025
Dianthus Therapeutics stock hits 52-week high at 40.0 USD By Investing.com - Investing.com Nigeria
Tue, 30 Sep 2025
Dianthus Therapeutics stock hits 52-week high at 40.0 USD By Investing.com - Investing.com South Africa
Tue, 30 Sep 2025
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - Yahoo Finance
Tue, 30 Sep 2025
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High - Here's Why - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 1.579e+007 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 5,980 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2981e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -18 % |
| Return on Assets (ttm) | 96.8 % |
| Return on Equity (ttm) | -23.4 % |
| Qtrly Rev. Growth | 4.85e+006 % |
| Gross Profit (p.s.) | -66.38 |
| Sales Per Share | -25.72 |
| EBITDA (p.s.) | 3.59259e+006 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -100 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.36 |
| Price to Cash Flow | 5 |
| Dividend | 0 |
| Forward Dividend | 5.12e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|